ABUS - Arbutus Biopharma Corp Stock Price, Fair Value and News

2.93USD-0.04 (-1.35%)Market Closed

Market Summary

USD2.93-0.04

Market Closed

-1.35%

ABUS Stock Price

View Fullscreen

ABUS RSI Chart

ABUS Valuation

Market Cap

525.9M

Price/Earnings (Trailing)

-7.22

Price/Sales (Trailing)

28.99

EV/EBITDA

-7.21

Price/Free Cashflow

-6.05

ABUS Price/Sales (Trailing)

ABUS Profitability

EBT Margin

-391.95%

Return on Equity

-68.71%

Return on Assets

-50.45%

Free Cashflow Yield

-16.53%

ABUS Fundamentals

ABUS Revenue

Revenue (TTM)

18.1M

Rev. Growth (Yr)

-65.65%

Rev. Growth (Qtr)

-53.95%

ABUS Earnings

Earnings (TTM)

-72.8M

Earnings Growth (Yr)

11.95%

Earnings Growth (Qtr)

3.94%

Breaking Down ABUS Revenue

Last 7 days

-2.7%

Last 30 days

11.8%

Last 90 days

29.1%

How does ABUS drawdown profile look like?

ABUS Financial Health

Current Ratio

5.87

ABUS Investor Care

Shares Dilution (1Y)

10.41%

Diluted EPS (TTM)

-0.44

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	33.1M	23.5M	22.2M	18.1M
2022	21.5M	33.4M	36.0M	39.0M
2021	7.5M	8.4M	10.2M	11.0M
2020	6.2M	6.5M	6.7M	6.9M
2019	5.2M	4.6M	9.5M	6.0M
2018	11.9M	12.1M	6.8M	5.9M
2017	3.8M	6.1M	8.4M	10.7M
2016	19.0M	13.2M	7.3M	1.5M
2015	15.2M	16.8M	16.5M	24.9M
2014	17.8M	16.7M	18.1M	15.0M
2013	17.9M	17.1M	16.3M	15.5M
2012	17.1M	17.5M	17.9M	18.3M
2011	20.2M	19.0M	17.8M	16.6M
2010	0	0	0	21.4M
2009	0	0	0	14.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Arbutus Biopharma Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 02, 2024	sims karen	sold	-10,077	2.3125	-4,358	chief medical officer
Feb 02, 2024	mcelhaugh michael j.	sold	-23,504	2.3125	-10,164	interim president & ceo
Feb 02, 2024	sofia michael j.	sold	-23,083	2.3125	-9,982	chief scientific officer
Feb 02, 2024	hastings david c	sold	-22,183	2.3125	-9,593	chief financial officer
Feb 01, 2024	sims karen	acquired	-	-	101,000	chief medical officer
Feb 01, 2024	mcelhaugh michael j.	acquired	-	-	123,800	interim president & ceo
Feb 01, 2024	sofia michael j.	acquired	-	-	109,500	chief scientific officer
Feb 01, 2024	naftzger j. christopher	acquired	-	-	95,100	general counsel and cco
Feb 01, 2024	hastings david c	acquired	-	-	112,500	chief financial officer
Feb 01, 2023	collier william h.	acquired	-	-	216,500	president and ceo

Which funds bought or sold ABUS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 12, 2024	HARBOR INVESTMENT ADVISORY, LLC	unchanged	-	64.00	2,072	-%
Apr 12, 2024	Financial Synergies Wealth Advisors, Inc.	reduced	-51.02	-7,838	9,288	-%
Apr 05, 2024	CWM, LLC	added	1,086	4,000	4,000	-%
Apr 05, 2024	GAMMA Investing LLC	unchanged	-	39.00	482	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	new	-	520	520	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.69	2,897,720	14,972,200	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	23.72	217,533	632,950	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	added	1.1	30,985	157,438	-%
Feb 26, 2024	Virtu Financial LLC	new	-	45,000	45,000	-%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	added	11.24	20,000	75,000	-%

Are Funds Buying or Selling ABUS?

Are funds buying ABUS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ABUS

No. of Funds

Unveiling Arbutus Biopharma Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	two seas capital lp	5.4%	9,041,927	SC 13G/A
Feb 14, 2024	whitefort capital management, lp	7.9%	13,197,062	SC 13G/A
Feb 12, 2024	blackrock inc.	6.2%	10,390,300	SC 13G/A
Nov 21, 2023	two seas capital lp	5.7%	9,503,103	SC 13G
Sep 11, 2023	whitefort capital management, lp	6.0%	10,013,899	SC 13G
Feb 03, 2023	blackrock inc.	5.6%	8,700,392	SC 13G
Feb 14, 2022	rtw investments, lp	1.7%	2,504,493	SC 13G/A
Oct 20, 2021	roivant sciences ltd.	29.1%	38,847,462	SC 13D/A
Feb 16, 2021	foresite capital fund iv, l.p.	0%	0	SC 13G/A
Feb 12, 2021	rtw investments, lp	7.05%	5,978,355	SC 13G/A

Recent SEC filings of Arbutus Biopharma Corp

View All Filings

Date Filed	Form Type	Document
Apr 10, 2024	DEFA14A	DEFA14A
Apr 10, 2024	DEF 14A	DEF 14A
Apr 04, 2024	8-K	Current Report
Mar 05, 2024	10-K	Annual Report
Feb 29, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 12, 2024	SC 13G/A	Major Ownership Report
Feb 05, 2024	4	Insider Trading
Feb 05, 2024	4	Insider Trading

Peers (Alternatives to Arbutus Biopharma Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.7B	6.8B	-0.04%	-27.89%	-8.41	5.79	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.5B	1.8B	-1.63%	-28.69%	-42.01	10.12	76.23%	61.08%
BMRN	17.2B	2.4B	8.39%	-9.36%	102.31	7.09	15.42%	18.43%
INCY	11.9B	3.7B	-8.82%	-29.04%	20	3.23	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-8.69%	-36.86%	-11.82	15.75	425.83%	18.94%
BBIO	4.4B	-	-8.20%	68.33%	-6.81	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-8.92%	-2.36%	-13.62	12.04	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.30%	-24.47%	-9.88	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-11.77%	-45.95	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-3.36%	-14.10%	25.63	4.6	85.90%	-14.05%
NVAX	557.0M	983.7M	-24.76%	-57.93%	-1.02	0.57	-50.36%	17.16%
CRBP	432.8M	881.7K	-5.56%	294.36%	-9.7	466.16	-77.61%	-5.33%
INO	225.3M	4.9M	-10.24%	-14.54%	-1.67	46.29	-54.97%	51.72%
IBIO	6.8M	2.1M	86.67%	92.16%	-0.25	2.14	-13.45%	66.37%

Arbutus Biopharma Corp News

Latest updates

Arbutus Biopharma Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-54.0%	2,145,000	4,658,000	4,651,000	6,687,000	6,245,000	5,952,000	14,241,000	12,581,000	3,206,000	3,340,000	2,329,000	2,113,000	2,386,000	1,523,000	1,514,000	1,491,000	3,988,500	6,486,000	653,000	679,000	1,678,000
Operating Expenses	-12.7%	22,892,000	26,216,000	23,036,000	24,100,000	28,807,000	23,763,000	28,350,000	23,555,000	24,002,000	21,748,000	20,971,000	17,789,000	18,687,000	16,740,000	14,655,000	14,638,000	14,653,000	94,086,000	21,298,000	19,875,000	18,581,000
S&GA Expenses	-12.7%	5,101,000	5,842,000	5,980,000	5,552,000	4,249,000	3,493,000	5,200,000	4,892,000	4,597,000	4,183,000	4,478,000	3,878,000	3,661,000	4,065,000	3,566,000	3,553,000	1,877,000	3,249,000	8,189,000	4,412,000	5,927,000
R&D Expenses	-12.9%	17,564,000	20,169,000	17,692,000	18,275,000	22,949,000	20,055,000	22,942,000	18,462,000	19,212,000	16,709,000	15,799,000	13,782,000	16,392,000	12,065,000	10,465,000	10,416,000	12,418,000	17,731,000	12,740,000	14,712,000	11,063,000
EBITDA Margin	-23.1%	-3.82	-3.10	-2.96	-2.09	-1.76	-1.90	-2.04	-3.15	-6.13	-6.60	-7.94	-8.04	-	-	-	-	-	-	-	-	-
Interest Expenses	-4.3%	44,000	46,000	171,000	198,000	309,000	429,000	482,000	506,000	560,000	762,000	763,000	772,000	797,000	1,074,000	1,099,000	1,041,000	994,000	1,100,000	2,000	12,000	122,000
Income Taxes	-	-	-	-	-	-	-	-	4,444,000	-	-	-	-	-	-	-	-	-	-12,656,000	-	-	-
Earnings Before Taxes	100.0%	-	-20,104,000	-17,094,000	-16,339,000	-	-17,567,000	-14,192,000	-11,321,000	-	-19,158,000	-19,387,000	-16,381,000	-17,042,000	-18,755,000	-14,087,000	-13,861,000	-24,654,000	-95,159,000	-23,315,000	-23,251,000	-18,249,000
EBT Margin	-22.6%	-3.92	-3.20	-3.06	-2.17	-1.84	-2.00	-2.16	-3.35	-6.55	-7.08	-8.57	-8.79	-	-	-	-	-	-	-	-	-
Net Income	3.9%	-19,312,000	-20,104,000	-17,094,000	-16,339,000	-21,932,000	-17,567,000	-14,192,000	-15,765,000	-21,321,000	-19,158,000	-19,387,000	-16,381,000	-17,042,000	-18,755,000	-14,087,000	-13,861,000	-24,654,000	-82,503,000	-23,315,000	-23,251,000	-18,249,000
Net Income Margin	-18.3%	-4.02	-3.39	-3.10	-2.11	-1.78	-1.91	-2.11	-3.52	-6.94	-7.08	-8.57	-8.79	-	-	-	-	-	-	-	-	-
Free Cashflow	20.7%	-17,292,000	-21,816,000	-20,418,000	-27,418,000	-17,124,000	-18,783,000	-20,505,000	20,544,000	-19,664,000	-16,056,000	-14,641,000	-17,980,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-9.0%	144	159	177	191	195	204	216	237	204	166	135	146	137	131	98.00	103	106	117	193	209	228
Current Assets	-6.8%	132	142	159	153	151	141	158	173	161	127	83.00	137	128	121	86.00	88.00	94.00	94.00	100	112	129
Cash Equivalents	49.9%	26.00	18.00	27.00	41.00	31.00	24.00	47.00	81.00	109	78.00	31.00	79.00	52.00	97.00	46.00	26.00	32.00	90.00	79.00	84.00	37.00
Net PPE	-7.1%	5.00	5.00	5.00	5.00	5.00	5.00	5.00	6.00	6.00	6.00	7.00	7.00	7.00	7.00	8.00	8.00	9.00	9.00	9.00	10.00	10.00
Goodwill	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	22.00	22.00	22.00
Liabilities	-2.3%	38.00	39.00	42.00	47.00	59.00	58.00	63.00	71.00	35.00	35.00	35.00	32.00	35.00	34.00	32.00	29.00	33.00	34.00	28.00	28.00	28.00
Current Liabilities	0.7%	22.00	22.00	25.00	25.00	33.00	28.00	30.00	32.00	11.00	10.00	9.00	7.00	10.00	8.00	6.00	4.00	8.00	9.00	9.00	9.00	11.00
Shareholder's Equity	-11.2%	106	119	135	144	137	146	153	166	169	130	101	114	102	97.00	66.00	73.00	73.00	84.00	164	181	200
Retained Earnings	-1.5%	-1,276	-1,257	-1,237	-1,220	-1,203	-1,181	-1,164	-1,150	-1,134	-1,112	-1,088	-1,065	-1,045	-1,025	-1,004	-986	-970	-942	-857	-831	-805
Additional Paid-In Capital	2.2%	81.00	80.00	77.00	74.00	72.00	71.00	69.00	67.00	65.00	64.00	64.00	62.00	61.00	60.00	58.00	57.00	55.00	55.00	54.00	50.00	48.00
Accumulated Depreciation	3.1%	12.00	12.00	11.00	11.00	11.00	10.00	10.00	10.00	9.00	9.00	8.00	8.00	8.00	7.00	7.00	9.00	6.00	9.00	8.00	7.00	7.00
Shares Outstanding	1.3%	170	168	167	165	157	151	149	148	145	101	95.00	93.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	288	-	-	-	290	-	-	-	238	-	-	-	130	-	-	-	118	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	20.6%	-17,292	-21,784	-19,559	-27,301	-16,990	-18,692	-20,293	20,619	-19,606	-16,036	-14,009	-17,881	-15,013	-12,174	-8,801	-15,453	-13,351	-23,470	-17,605	-16,580	-17,074
Share Based Compensation	-30.6%	1,723	2,483	2,964	2,131	1,667	1,715	2,064	1,736	1,431	1,615	1,743	1,635	1,431	1,688	1,597	1,445	-23.00	1,516	3,784	1,522	797
Cashflow From Investing	113.1%	22,225	10,429	1,441	16,678	12,682	-13,738	-13,830	-60,056	-8,121	15,969	-38,747	18,221	-49,976	14,097	23,371	-2,401	-58,822	16,155	9,972	61,033	38,483
Cashflow From Financing	126.5%	3,807	1,681	4,742	20,417	11,084	9,132	113	11,485	59,121	46,952	4,289	26,874	20,210	49,096	4,959	12,481	13,893	18,549	2,479	2,536	109

ABUS Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue
Revenues	$ 18,141	$ 39,019
Operating expenses
Research and development	73,700	84,408
General and administrative	22,475	17,834
Change in fair value of contingent consideration	69	2,233
Total operating expenses	96,244	104,475
Loss from operations	(78,103)	(65,456)
Other income
Interest income	5,688	2,192
Interest expense	(459)	(1,726)
Foreign exchange (loss) gain	25	(22)
Total other income	5,254	444
Loss before income taxes	(72,849)	(65,012)
Income tax expense	0	4,444
Net loss	$ (72,849)	$ (69,456)
Loss per share
Basic (in USD per share)	$ (0.44)	$ (0.46)
Diluted (in USD per share)	$ (0.44)	$ (0.46)
Weighted average number of common shares
Basic (in shares)	165,960,379	150,939,337
Diluted (in shares)	165,960,379	150,939,337
Comprehensive loss
Unrealized gain/(loss) on available-for-sale securities	$ 2,067	$ (2,153)
Comprehensive loss	$ (70,782)	(71,609)
Stock Option
Comprehensive loss
Number of additional shares authorized (in shares)	7,672,299
Collaborations and licenses
Revenue
Revenues	$ 14,274	31,366
Non-cash royalty revenue
Revenue
Revenues	$ 3,867	$ 7,653

ABUS Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 26,285	$ 30,776
Investments in marketable securities, current	99,718	116,137
Accounts receivable	1,776	1,352
Prepaid expenses and other current assets	4,248	2,874
Total current assets	132,027	151,139
Property and equipment, net of accumulated depreciation	4,674	5,070
Investments in marketable securities, non-current	6,284	37,363
Right of use asset	1,416	1,744
Other non-current assets	0	103
Total assets	144,401	195,419
Current liabilities:
Accounts payable and accrued liabilities	10,271	16,029
Deferred Revenue, Current	11,791	16,456
Lease liability, current	425	372
Total current liabilities	22,487	32,857
Liability related to sale of future royalties	6,953	10,365
Deferred Revenue, Noncurrent	0	5,999
Contingent consideration	7,600	7,531
Lease liability, non-current	1,343	1,815
Total liabilities	38,383	58,567
Stockholders’ equity
Common shares, Authorized: unlimited number without par value, Issued and outstanding: 144,987,736 (December 31, 2020: 89,678,722)	1,349,821	1,318,737
Additional paid-in capital	81,270	72,406
Deficit	(1,276,652)	(1,203,803)
Accumulated other comprehensive loss	(48,421)	(50,488)
Total stockholders' equity	106,018	136,852
Total liabilities and stockholders' equity	$ 144,401	$ 195,419

About Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

CEO	Mr. William H. Collier
WEBSITE	arbutusbio.com
INDUSTRY	Biotechnology
EMPLOYEES	96

Arbutus Biopharma Corp Frequently Asked Questions

What is the ticker symbol for Arbutus Biopharma Corp? What does ABUS stand for in stocks?

ABUS is the stock ticker symbol of Arbutus Biopharma Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Arbutus Biopharma Corp (ABUS)?

As of Tue Apr 16 2024, market cap of Arbutus Biopharma Corp is 525.91 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABUS stock?

You can check ABUS's fair value in chart for subscribers.

What is the fair value of ABUS stock?

You can check ABUS's fair value in chart for subscribers. The fair value of Arbutus Biopharma Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Arbutus Biopharma Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ABUS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Arbutus Biopharma Corp a good stock to buy?

The fair value guage provides a quick view whether ABUS is over valued or under valued. Whether Arbutus Biopharma Corp is cheap or expensive depends on the assumptions which impact Arbutus Biopharma Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABUS.

What is Arbutus Biopharma Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 16 2024, ABUS's PE ratio (Price to Earnings) is -7.22 and Price to Sales (PS) ratio is 28.99. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABUS PE ratio will change depending on the future growth rate expectations of investors.